Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Docetaxel nanoparticle - Cristal Therapeutics

Next Previous
Search
Drug Profile

Docetaxel nanoparticle - Cristal Therapeutics

Alternative Names: CPC 634; CriPec® docetaxel; Docetaxel containing CriPec® nanoparticles

Latest Information Update: 29 Aug 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cristal Therapeutics
  • Class Antineoplastics; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Ovarian cancer; Solid tumours

Most Recent Events

  • 07 Aug 2023 Cristal Therapeutics terminates a phase II trial in Ovarian cancer (Late stage disease, Second line therapy and greater) in Belgium, Netherlands and UK due to futility prior to August 2023 (IV) (NCT03742713)
  • 02 Jan 2023 No development reported - Phase-II for Ovarian cancer (Late-stage disease, Second-line therapy or greater) in Belgium (IV)
  • 02 Jan 2023 No development reported - Phase-II for Ovarian cancer (Late-stage disease, Second-line therapy or greater) in Netherlands (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top